Trending...
- Maryland: Preliminary Testing Confirms Highly Pathogenic Avian Influenza in Third Anne Arundel County Backyard Flock in 2025 - 107
- Where the Miami Dolphins Stand After Week 1
- RUNA Brings Celtic Spirit and American Roots to New Spire Stages
BALTIMORE ~ KeraLink International (KLI) has announced a $2.5 million seed funding for Pantheon Vision (PV), an early-stage ophthalmic medical device company established by KLI, to launch the development of a novel advancement to help eradicate corneal blindness in both developed and low- and middle-income countries (LMICs).
The funding will be used to develop bioengineered corneal implants to reduce reliance on donated corneal tissue – often unavailable in LMICs. This venture philanthropy strategy is part of KLI's PEN approach to eradicating corneal blindness: Prevention of corneal blindness, Early detection and treatment of corneal conditions, and Novel therapies that are effective and affordable for broad use in underserved and under-resourced LMICs.
Douglas J. Furlong, KLI Board Chairman said, "Development of novel therapeutic solutions is costly but critical to fulfilling our mission of eradicating corneal blindness. We are proud to support Pantheon Vision's promising work and anticipate a return on this investment that will allow us to fund additional innovative products, technologies, and services."
More on Marylandian
KLI President and CEO David Green added, "Working with generous donors and impact investors, we will fuse the power of market-based solutions with compassionate philanthropy to ensure corneal health in LMICs."
John Sheets, Ph.D., an ophthalmic industry veteran leads Pantheon Vision. He has led companies including Hoya and Elisar, as well as R&D organizations at Alcon, Bausch & Lomb, Johnson & Johnson; he also served the Food and Drug Administration heading its Office of Device Evaluation.
More than 12.7 million children and adults are blind because of corneal injuries or infections; millions more are blind in one eye or live with seriously impaired vision. KLI is striving towards eradicating corneal blindness with specific emphasis on low-and middle-income countries by advancing ground-breaking products, technologies, and services.
The funding will be used to develop bioengineered corneal implants to reduce reliance on donated corneal tissue – often unavailable in LMICs. This venture philanthropy strategy is part of KLI's PEN approach to eradicating corneal blindness: Prevention of corneal blindness, Early detection and treatment of corneal conditions, and Novel therapies that are effective and affordable for broad use in underserved and under-resourced LMICs.
Douglas J. Furlong, KLI Board Chairman said, "Development of novel therapeutic solutions is costly but critical to fulfilling our mission of eradicating corneal blindness. We are proud to support Pantheon Vision's promising work and anticipate a return on this investment that will allow us to fund additional innovative products, technologies, and services."
More on Marylandian
- ENTOUCH Completes $50 million Funding Round
- Teaming Agreement with Emtel Energy USA to Advance Thin-Film PV Energy Storage Capabilities; NASA agreements for Solar Space Tech; Ascent Solar $ASTI
- Nebuvex Acknowledges Platform "Too Secure" for Anonymous Traders; Institutional Investors Disagree
- Precision Antibody to Attend the World Clinical Biomarkers & CDx Summit 2025 in Boston
- From Tokyo to Berlin: FreeTo.Chat Unites Cultures with the World's First Confession VRX — EmojiStream™
KLI President and CEO David Green added, "Working with generous donors and impact investors, we will fuse the power of market-based solutions with compassionate philanthropy to ensure corneal health in LMICs."
John Sheets, Ph.D., an ophthalmic industry veteran leads Pantheon Vision. He has led companies including Hoya and Elisar, as well as R&D organizations at Alcon, Bausch & Lomb, Johnson & Johnson; he also served the Food and Drug Administration heading its Office of Device Evaluation.
More than 12.7 million children and adults are blind because of corneal injuries or infections; millions more are blind in one eye or live with seriously impaired vision. KLI is striving towards eradicating corneal blindness with specific emphasis on low-and middle-income countries by advancing ground-breaking products, technologies, and services.
Filed Under: Business
0 Comments
Latest on Marylandian
- New Analysis Reveals the Complex Forces Driving the 'Great Human Reshuffle'
- Elevate Unveils GroundComm X30 at 2025 International GSE Expo in Las Vegas
- Meet Donna L. Quesinberry: Angelic Realms and Transcendent Verse
- How DonnaInk Elevates Indie Authors with Editorial Precision
- NEW power supply release from Kepco Dynatronix - HSP Advanced
- St. Augustine Honors Hispanic Heritage Month
- Vesica Health Receives AUA Guideline Inclusion
- Steward's Plumbing Sponsors the 2025 Samson Challenge, Bringing Community, Fitness, and Fun Together in Albuquerque
- Maryland: Poultry Farmers Urged to Practice Enhanced Biosecurity
- 10xLaw.com Extends Employment Opportunity to Kim Kardashian
- DecisionPoint Technologies Accelerates Growth with Acquisition of Acuity Technologies
- CCHR: Involuntary Commitment Is Eugenics Repackaged as "Mental Health Care"
- Q2 2025 Industry Impact Report Underscores Semiconductor Expansion, Talent Development and Sustainability Milestones
- 84 Ethiopian Churches Change Signboards to Shincheonji Church of Jesus
- BTXSGG Outlines Four-Pillar Framework to Enhance Digital Asset Security and Compliance
- NJTRX Positions for Next-Generation Asset Trading with U.S. Regulatory Framework
- Poncho Tha Popstar: The West's Next King
- Physician-Turned-Patient Launches Advocacy Campaign to Spotlight Disability Insurance Barriers
- Thorn Ridge® Creates a World of Legends & Lore
- Twice the Laughs: Comedy Star Don Barnhart Rotates Residency at Both Delirious Comedy Club Locations in Las Vegas